Search Results for:
-
Santhera Withdraws Raxone MAA, Plans Resubmission
It's a number that would be of interest to the CHMP," Santhera CEO Thomas Meier told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, March 27, 2013 -
GW Pharma Files for $50M IPO with Sativex in Phase III
investors," Justin Gover, CEO told BioWorld InternationalBy Nuala Moran | BioWorld International | Wednesday, March 20, 2013 -
ThromboGenics Banks $59M Milestone on EU Approval
Ninety-five percent of them get acquired – that's just a given," Jan De Kerpel, analyst at KBC Securities in Brussels, Belgium, told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, March 20, 2013 -
Anticancer Drugs May Hold Key to Parasite Treatment
Matthew Berriman, a co-author of the paper, and group leader for parasite genomics at the Wellcome Trust Sanger Institute, told BioWorld International: "This work lays everything out for the entire tapeworm research community to mine, and provides a shortcut to drug discoveryBy Sharon Kingman | BioWorld International | Wednesday, March 20, 2013 -
Safinamide Hits Endpoints in Two Parkinson's Phase III Trials
Ravi Anand, chief medical officer at Milan, Italy-based Newron told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, March 20, 2013 -
Helmedix Lands Seed Funding to Back Helminth Peptide R&D
By the end, we hope to have a lead candidate, know the mode of action and be ready to consider clinical development," Thompson told BioWorld InternationalBy Nuala Moran | BioWorld International | Wednesday, March 20, 2013 -
Grants, Contracts And Awards To Biotech Companies: Oct. 1, 2012 - March 14, 2013
Company (Location) Funding Institution Amount (US$M) Type Details Date OCTOBER Addex Therapeutics SA (Geneva) Swiss Commission for Technology and Innovation CHF0.7 ($0.748) Grant For development of allosteric modulators for neurodegenerative and psychiatric diseases 10/3/12 Advanced Cancer Therapeutics Inc. (Louisville, Ky.) National Cancer Institute $0.158 Phase I SBIR grant To support the development of an inhibitor of glycolysis targeting 6-phosphofructo-2 kinase/fructose 2,6-biphosphatase 3BioWorld Insight | Monday, March 18, 2013 -
Newly Identified Enzyme Could Rival PARPs as a Drug Target
Ivan Ahel, group leader at the Paterson Institute for Cancer Research at the University of Manchester in the UK, told BioWorld International: "The question is, can we intentionally inhibit this protein and others that operate in the same pathwayBio Perspectives | Wednesday, March 13, 2013 -
Planning for Global Expansion, Cell Medica Recruits New CMO
When we approached him, his view was, 'This is a company with an excellent shot at commercializing cell therapies and that's what I want to do.' So he's completely committed to the cause," CEO Gregg Sando told BioWorld International...Cell Medica is expanding operations after raising $26.5 million in July 2012 in a mixture of public and private funding, including a grant from the Cancer Prevention and Research Institute of Texas, under which it is setting up a manufacturing facility and will run aBy Nuala Moran | BioWorld International | Wednesday, March 13, 2013 -
Biotica's Polyketide Programs Find New Home at NeuroVive
Mikael Bronnegard, CEO of Lund, Sweden-based NeuroVive, told BioWorld International that the company has yet to decide whether to take that forward itself or to seek a partner...handed back to Biotica almost two years ago. (See BioWorld International, Aug. 10, 2011.)By Cormac Sheridan | BioWorld International | Wednesday, March 13, 2013 -
Newly Identified Enzyme Could Rival PARPs as a Drug Target
Ivan Ahel, group leader at the Paterson Institute for Cancer Research at the University of Manchester in the UK, told BioWorld International: "The question is, can we intentionally inhibit this protein and others that operate in the same pathwayBy Sharon Kingman | BioWorld International | Wednesday, March 13, 2013 -
U.K. Catalyst Fund Brings $70M to Biotech Firms
The de-risking of the Biomedical Catalyst grants is attracting new investors," he told BioWorld InternationalBy Nuala Moran | BioWorld International | Wednesday, March 13, 2013 -
AbbVie, InterMune Sue EMA on Data Confidentiality
There are certain elements that require protection, mainly related to personal patient data," an EMA spokeswoman told BioWorld International...I don't want to comment on that until the heads of argument are available," AbbVie spokesman Dirk Van Eeden told BioWorld InternationalBioWorld International | Wednesday, March 13, 2013 -
NeuroVive Picks Up Biotica Polyketide Assets
handed back to Biotica almost two years ago. (See BioWorld International, Aug. 10, 2011.)By Cormac Sheridan | BioWorld Today | Tuesday, March 12, 2013 -
TopoTarget Stock Surges on Trickle of Data for Belinostat
You definitely have to do confirmatory studies to confirm it," Vadsholt told BioWorld InternationalBio Perspectives | Wednesday, March 6, 2013 -
TopoTarget Stock Surges on Trickle of Data for Belinostat
You definitely have to do confirmatory studies to confirm it," Vadsholt told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, March 6, 2013 -
Ablynx Pads Cash Reserves to Push RA Drug into Phase IIb
We wanted to keep our options open on ALX-0061, and this now allows us to carry on with preparations for the next trial," CEO Edwin Moses told BioWorld InternationalBy Nuala Moran | BioWorld International | Wednesday, March 6, 2013 -
Concert Sings 'All That Jazz' with D-SXB Licensing Deal
One of the takeaways from the Avanir experience is that when a partner has a chance to look at the molecules and see that they are differentiated – that they are getting better properties from the deuterated compound than from the non-deuterated agent – that can create a lot of excitement," Tung told BioWorld InternationalBy Marie Powers | BioWorld International | Wednesday, March 6, 2013 -
Rare Diseases Get $187M from European Commission
Speaking from the conference, Alastair Kent, director of Genetic Alliance UK, told BioWorld International: "This is good newsBy Nuala Moran | BioWorld International | Wednesday, March 6, 2013 -
Study: Treating Psychosis with Anti-Inflammatories Possible
Catharina Lavebratt, associate professor in the department of molecular medicine and surgery at the Karolinska Institute in Stockholm, Sweden, told BioWorld International: "We have found a genetic variant that doubles the risk of developing psychotic features among people with bipolar disorderBioWorld International | Wednesday, March 6, 2013
Category
Current Filters
- xBioWorld International
Related Keywords
Categories
- x BioWorld International (5382)
- x BioWorld Insight (589)
- x BioWorld Today (330)
- x Bio Perspectives (191)
- x State of the Industry Report (47)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.